ATE338563T1 - Verfahren zur behandlung von patienten die unter multipler sklerose leiden mit konsensus- interferon - Google Patents

Verfahren zur behandlung von patienten die unter multipler sklerose leiden mit konsensus- interferon

Info

Publication number
ATE338563T1
ATE338563T1 AT98933344T AT98933344T ATE338563T1 AT E338563 T1 ATE338563 T1 AT E338563T1 AT 98933344 T AT98933344 T AT 98933344T AT 98933344 T AT98933344 T AT 98933344T AT E338563 T1 ATE338563 T1 AT E338563T1
Authority
AT
Austria
Prior art keywords
multiple sclerosis
patients suffering
treating patients
consensus interferon
consensus
Prior art date
Application number
AT98933344T
Other languages
English (en)
Inventor
David Martin
Norman L Fischer
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE338563T1 publication Critical patent/ATE338563T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT98933344T 1997-08-15 1998-07-15 Verfahren zur behandlung von patienten die unter multipler sklerose leiden mit konsensus- interferon ATE338563T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/911,893 US6013253A (en) 1997-08-15 1997-08-15 Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist

Publications (1)

Publication Number Publication Date
ATE338563T1 true ATE338563T1 (de) 2006-09-15

Family

ID=25431058

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98933344T ATE338563T1 (de) 1997-08-15 1998-07-15 Verfahren zur behandlung von patienten die unter multipler sklerose leiden mit konsensus- interferon

Country Status (17)

Country Link
US (1) US6013253A (de)
EP (1) EP1003546B1 (de)
JP (1) JP3813440B2 (de)
KR (1) KR100415636B1 (de)
CN (1) CN1183963C (de)
AT (1) ATE338563T1 (de)
AU (1) AU741074B2 (de)
CA (1) CA2299361C (de)
CY (1) CY1107314T1 (de)
DE (1) DE69835823T2 (de)
DK (1) DK1003546T3 (de)
ES (1) ES2267188T3 (de)
HU (1) HU229045B1 (de)
IL (2) IL134345A0 (de)
PT (1) PT1003546E (de)
TW (1) TW474817B (de)
WO (1) WO1999008702A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214658B2 (en) * 2004-07-06 2007-05-08 Tact Ip, Llc Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection
US6982089B2 (en) 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
US6471961B1 (en) * 1999-02-24 2002-10-29 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US20030007972A1 (en) * 1999-02-24 2003-01-09 Edward Tobinick Cytokine antagonists and other biologics for the treatment of bone metastases
US20020131954A1 (en) * 2000-05-02 2002-09-19 Tobinick Edward L. Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US20030027755A1 (en) * 2000-12-08 2003-02-06 Jian Guan Compositions and methods for the rescue of white matter
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
EP1401808B1 (de) 2001-05-24 2009-07-08 Neuren Pharmaceuticals Limited Gpe-analoga und peptidomimetika
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7230167B2 (en) 2001-08-31 2007-06-12 Syngenta Participations Ag Modified Cry3A toxins and nucleic acid sequences coding therefor
SI1471974T1 (sl) * 2002-02-06 2007-12-31 Ares Trading Sa Tumorje nekrotizirajoäśi faktor, kombiniran z interferonom, pri demielinizirajoäśih boleznih
WO2004035086A2 (en) * 2002-10-16 2004-04-29 Hunter Samuel F Method for treatment of demyelinating central nervous system disease using gm-csf
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
DE102004008168B4 (de) * 2004-02-19 2015-12-10 Voxeljet Ag Verfahren und Vorrichtung zum Auftragen von Fluiden und Verwendung der Vorrichtung
US7879320B2 (en) * 2004-05-17 2011-02-01 Ares Trading S.A. Hydrogel interferon formulations
US7731948B2 (en) 2004-06-01 2010-06-08 Ares Trading S.A. Stabilized interferon liquid formulations
EA012281B1 (ru) 2004-06-01 2009-08-28 Арес Трейдинг С.А. Способ стабилизации белков
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
BG66458B1 (bg) 2005-03-21 2014-10-31 Иван Иванов Средство за конкурентно инхибиране на ендогенен гама интерферон
EP1901769A2 (de) * 2005-05-02 2008-03-26 Avigen, Inc. Verwendung von peptiden von cytokinen bei der behandlung von schmerzen und neurodegenerativen erkrankungen
US20080219952A1 (en) 2005-08-26 2008-09-11 Ares Trading S.A. Process For the Preparation of Glycosylated Interferon Beta
EP1933860A2 (de) * 2005-09-01 2008-06-25 Ares Trading S.A. Behandlung von optikusneuritis
MX2008014971A (es) 2006-05-24 2008-12-05 Serono Lab Regimen de cladribine para tratar esclerosis multiple.
RS52417B (sr) * 2007-12-20 2013-02-28 Merck Serono S.A. Formulacije peg-interferona-beta
US9359421B2 (en) 2008-04-08 2016-06-07 Tigo Gmbh Suppressor of the endogenous interferon-gamma
BG66517B1 (bg) 2008-04-08 2016-02-29 Tigo Gmbh Супресор на ендогенния човешки гама - интерферон
WO2013008102A2 (en) 2011-07-14 2013-01-17 R.E.D. Laboratories N.V../ S.A. Methods and compositions for evaluating and/or treating chronic immune diseases
SI3021873T1 (sl) 2013-07-18 2018-12-31 Xalud Therapeutics, Inc. Sestavek za zdravljenje vnetne sklepne bolezni
BG67190B1 (bg) 2017-03-29 2020-11-16 Tigo Gmbh Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон
AR113906A1 (es) 2017-11-24 2020-06-24 Merck Patent Ges Mit Beschraenkter Haftung Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple
IL301246A (en) 2020-09-10 2023-05-01 Merck Patent Gmbh Treatment regimen with cladribine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
HK1006856A1 (en) * 1989-11-29 1999-03-19 Amgen Inc. Production of recombinant human interleukin-1 inhibitor
WO1991017184A1 (en) * 1990-04-27 1991-11-14 The Upjohn Company Modified interleukin-1 inhibitors
ES2128348T3 (es) * 1990-10-17 1999-05-16 Amgen Inc Obtencion de composiciones para el tratamiento de alteraciones de la proliferacion celular.
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5858355A (en) * 1990-12-20 1999-01-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education IRAP gene as treatment for arthritis
AU1674292A (en) * 1991-03-15 1992-10-21 Synergen, Inc. Pegylation of polypeptides
CA2118119C (en) * 1992-04-30 2001-07-31 Robert C. Thompson Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
ATE257389T1 (de) * 1992-09-17 2004-01-15 Amgen Inc Pharmazeutische zusammensetzungen mit interleukin-1 inhibitoren
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
WO1994020517A1 (en) * 1993-03-08 1994-09-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for treating a connective tissue of a mammalian host
CA2157758A1 (en) * 1993-03-19 1994-09-29 Louis Chedid Compositions for use in human therapeutics, characterised by the association of a muramyl peptide with a cytokine
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
FR2706772A1 (en) * 1993-06-22 1994-12-30 Vacsyn Sa Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin.
DE69521880T2 (de) * 1994-02-08 2002-01-03 Amgen Inc., Thousand Oaks Orales verabreichungssystem von chemischmodifizierten proteinen g-csf

Also Published As

Publication number Publication date
CY1107314T1 (el) 2012-11-21
WO1999008702A1 (en) 1999-02-25
TW474817B (en) 2002-02-01
CN1267225A (zh) 2000-09-20
DK1003546T3 (da) 2006-10-30
PT1003546E (pt) 2006-12-29
EP1003546B1 (de) 2006-09-06
HUP0002755A3 (en) 2001-11-28
KR100415636B1 (ko) 2004-01-24
AU8300698A (en) 1999-03-08
IL134345A (en) 2011-03-31
EP1003546A1 (de) 2000-05-31
CA2299361A1 (en) 1999-02-25
JP3813440B2 (ja) 2006-08-23
ES2267188T3 (es) 2007-03-01
DE69835823T2 (de) 2007-08-09
HUP0002755A2 (hu) 2000-12-28
JP2001515047A (ja) 2001-09-18
US6013253A (en) 2000-01-11
AU741074B2 (en) 2001-11-22
DE69835823D1 (de) 2006-10-19
HU229045B1 (en) 2013-07-29
CA2299361C (en) 2009-09-29
IL134345A0 (en) 2001-04-30
CN1183963C (zh) 2005-01-12
KR20010030563A (ko) 2001-04-16
HK1030157A1 (en) 2001-04-27

Similar Documents

Publication Publication Date Title
DE69835823D1 (de) Verfahren zur behandlung von patienten die unter multipler sklerose leiden mit konsensus-interferon
ATE161192T1 (de) Verfahren zur behandlung einer durch lfa-1 vermittelten störung
ATE219373T1 (de) Medikamente zur behandlung von autoimmunerkrankungen mit interferon-tau
DE69736712D1 (de) Verfahren zur milderung von neuropatischen schmerz mit prosaposin verwandten peptiden
ATE209483T1 (de) Behandlung von multipler sklerose
ATE207352T1 (de) Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
IL161889A0 (en) Method for treating diseases with omega interferon
DE69837322D1 (de) Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
SE9603725D0 (sv) New teatment
DE60140960D1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
DE3583220D1 (de) Verwendung von dipeptidderivaten fuer die herstellung von arzneimitteln zur behandlung von an amyotropher lateralsklerose erkrankten.
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
ATE271879T1 (de) Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen
DE60015791D1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE69619187D1 (de) Verfahren zur behandlung von motorischen defiziten
DE60144493D1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
ATE167628T1 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
DE60013636D1 (de) Verfahren zur behandlung endzünlicher darmerkrankungen durch verwendung von choleratoxin untereinheit b
ATE306269T1 (de) Behandlung der exzessiven aggressivität mit olanzapine
DE69430807D1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen
ATE250416T1 (de) Verfahren zur behandlung und vorbeugung von neurodegenerativen erkrankungen durch verabreichung von einem thiazolidin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1003546

Country of ref document: EP